{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-283649","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.630951+00:00","generated_at":"2026-06-21T19:22:29.390461+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alaunos reports Q3 net loss $8.9M; first objective response in TCR-T Library trial","bullets":["Q3 2022 net loss $8.9M ($0.04/sh) vs $22.7M ($0.11/sh) in Q3 2021; revenue $2.9M from darinaparsin milestone.","First patient with NSCLC achieved >50% tumor regression at 12 weeks with Sleeping Beauty TCR-T cells targeting KRAS G12D.","TCR-T cell persistence observed: ~30% of blood T-cells at 24 weeks in patient 1; manageable safety, no ICANS.","Manufacturing capacity doubled to produce two products simultaneously; IND amendment in 4Q22 to add two TCRs and switch to cryopreserved process (26 days vs 30).","Cash $37.8M plus restricted cash $13.9M; operating cash burn $6.1M in Q3 2022, down 36% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-283649","json":"https://secwatch.observer/filing/0001193125-22-283649.json","markdown":"https://secwatch.observer/filing/0001193125-22-283649.md","text":"https://secwatch.observer/filing/0001193125-22-283649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312522283649/0001193125-22-283649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312522283649/d411392d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:22:29.390461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1801c68d2e5c9cb6113f9cb7829da3b6ecff3dad","claim":"Alaunos Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $2.9 million.","evidence_excerpt":"Collaboration revenue was $2.9 million for the third quarter of 2022, compared to $0.4 million for the third quarter of 2021, an increase of 631%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312522283649/0001193125-22-283649-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$2.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}